0000899243-23-003525.txt : 20230202 0000899243-23-003525.hdr.sgml : 20230202 20230202174108 ACCESSION NUMBER: 0000899243-23-003525 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230131 FILED AS OF DATE: 20230202 DATE AS OF CHANGE: 20230202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Richard Robert E. CENTRAL INDEX KEY: 0001816151 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39273 FILM NUMBER: 23582518 MAIL ADDRESS: STREET 1: C10 LYRA THERAPEUTICS, INC. STREET 2: 1480 ALSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001327273 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 ARSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-373-4600 MAIL ADDRESS: STREET 1: 480 ARSENAL WAY CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: 480 Biomedical, Inc. DATE OF NAME CHANGE: 20120927 FORMER COMPANY: FORMER CONFORMED NAME: Arsenal Vascular, Inc. DATE OF NAME CHANGE: 20110826 FORMER COMPANY: FORMER CONFORMED NAME: Arsenal Medical, Inc. DATE OF NAME CHANGE: 20090414 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-31 0 0001327273 Lyra Therapeutics, Inc. LYRA 0001816151 Richard Robert E. C/O LYRA THERAPEUTICS, INC. 480 ARSENAL WAY WATERTOWN MA 02472 0 1 0 0 SVP, Technical Operations Common Stock 2023-01-31 4 A 0 30000 0.00 A 30000 D Stock Option 2.85 2023-01-31 4 A 0 45000 0.00 A 2033-01-30 Common Stock 45000 45000 D Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in four (4) equal annual installments on the first four anniversaries of the grant date such that the RSUs will fully vest on January 31, 2027. This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 31, 2023. /s/ Jason Cavalier, Attorney-in-Fact for Robert E. Richard, Ph.D. 2023-02-02